Cost-Effectiveness of ENTEREX® HPT, A Specialized Nutrition Supplement, for Patients with Liver Disease in Mexico

Abstract

These costs yielded an ICER of -4170 for the SOF+LDV+RBV, -9515 for the SOF+DCV and -2289 for the SOF+RBV. SOF+DCV regimen was the most cost saving option for cirrhotic and non-cirrhotic patients than the other treatment regimens. Deterministic sensitivity analyses remain robust. ConClusions: This study concludes that SOF+DCVregimen is the most cost saving option that yields the most favorable future health economic outcomes compared to the SOF+pegIFN+RBV group across a broad spectrum of patients, including those with cirrhosis.